| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-E*0103 & B2M | Unconjugated Human HLA-E*01:03 & B2M Monomer Protein (Peptide free, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |||
| HLA-E*0103 & B2M | Biotinylated Human HLA-E*01:03&B2M Monomer Protein (Peptide free, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |||
| HLA-E*0103 & B2M | PE-Labeled Human HLA-E*01:03&B2M Tetramer Protein (Peptide free) | Human | HEK293 | $410.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Aldafermin | NGM-282; M70; M-70; NGM282 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Liver Cirrhosis, Biliary; Constipation; Irritable Bowel Syndrome; Metabolic Dysfunction-Associated Steatotic Liver Disease; Renal Insufficiency; Bile acid malabsorption (BAM); Fibrosis; Cholangitis, Sclerosing; Diarrhea; Hepatic Insufficiency; Malabsorption Syndromes; Diabetes Mellitus | Details |
